Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Top Cited Papers
- 24 November 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 385 (22), 2036-2046
- https://doi.org/10.1056/nejmoa2103425
Abstract
Patients with von Hippel–Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to VHL gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α).Keywords
Funding Information
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
This publication has 22 references indexed in Scilit:
- Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR groupOncotarget, 2016
- Targeting renal cell carcinoma with a HIF-2 antagonistNature, 2016
- On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer modelsNature, 2016
- Management of von Hippel-Lindau Disease: An Interdisciplinary ReviewOncology Research and Treatment, 2014
- Pilot trial of sunitinib therapy in patients with von Hippel–Lindau diseaseAnnals of Oncology, 2011
- von Hippel–Lindau disease: A clinical and scientific reviewEuropean Journal of Human Genetics, 2011
- Hypoxia-inducible factor–2 (HIF-2) regulates hepatic erythropoietin in vivoJCI Insight, 2007
- HIF-2α regulates murine hematopoietic development in an erythropoietin-dependent mannerBlood, 2005
- von Hippel-Lindau DiseaseMayo Clinic Proceedings, 2000
- von Hippel-Lindau DiseaseMayo Clinic Proceedings, 2000